167 related articles for article (PubMed ID: 37526545)
21. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas.
Takano K; Kinoshita M; Arita H; Okita Y; Chiba Y; Kagawa N; Fujimoto Y; Kishima H; Kanemura Y; Nonaka M; Nakajima S; Shimosegawa E; Hatazawa J; Hashimoto N; Yoshimine T
AJNR Am J Neuroradiol; 2016 Jan; 37(1):44-50. PubMed ID: 26381556
[TBL] [Abstract][Full Text] [Related]
23. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Kebir S; Lazaridis L; Weber M; Deuschl C; Stoppek AK; Schmidt T; Mönninghoff C; Blau T; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Stuschke M; Antoch G; Sure U; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Herrmann K; Glas M
Clin Nucl Med; 2019 Jun; 44(6):e375-e381. PubMed ID: 30985412
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of O-(2-[
Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C
Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078
[TBL] [Abstract][Full Text] [Related]
26. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
27. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
[TBL] [Abstract][Full Text] [Related]
28. Quantitative volumetric analysis of gliomas with sequential MRI and ¹¹C-methionine PET assessment: patterns of integration in therapy planning.
Arbizu J; Tejada S; Marti-Climent JM; Diez-Valle R; Prieto E; Quincoces G; Vigil C; Idoate MA; Zubieta JL; Peñuelas I; Richter JA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):771-81. PubMed ID: 22258713
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
[TBL] [Abstract][Full Text] [Related]
30. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
32. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI.
Khangembam BC; Sharma P; Karunanithi S; Singhal A; Das CJ; Kumar P; Julka PK; Bandopadhyaya GP; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2013 Nov; 34(11):1046-54. PubMed ID: 24025920
[TBL] [Abstract][Full Text] [Related]
33. Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
Schinkelshoek M; Lopci E; Clerici E; Alongi F; Mancosu P; Rodari M; Navarria P; van der Hiel B; Scorsetti M; Chiti A
Tumori; 2014; 100(6):636-44. PubMed ID: 25688497
[TBL] [Abstract][Full Text] [Related]
34. Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.
Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Goenka A; Gupta DK; Malhotra A; Bal C
Eur Radiol; 2013 Sep; 23(9):2628-35. PubMed ID: 23624623
[TBL] [Abstract][Full Text] [Related]
35. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
[TBL] [Abstract][Full Text] [Related]
36. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
Roessler K; Gatterbauer B; Becherer A; Paul M; Kletter K; Prayer D; Hoeftberger R; Hainfellner J; Asenbaum S; Knosp E
Minim Invasive Neurosurg; 2007 Oct; 50(5):273-80. PubMed ID: 18058643
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Performance of [
Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
[TBL] [Abstract][Full Text] [Related]
38. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
[TBL] [Abstract][Full Text] [Related]
39. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and
Qiao Z; Zhao X; Wang K; Zhang Y; Fan D; Yu T; Shen H; Chen Q; Ai L
AJNR Am J Neuroradiol; 2019 Feb; 40(2):253-259. PubMed ID: 30655259
[TBL] [Abstract][Full Text] [Related]
40. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
